Verici Dx plc
("Verici Dx" or the "Company")
Successful completion of ISO 27001 surveillance audit
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has successfully completed the annual surveillance audit for its ISO 27001:2022 certification.
ISO 27001 is a globally recognised standard specifying data privacy and security requirements for an Information Security Management System ("ISMS"). The annual surveillance audit aims to confirm that the Company is following the highest level of standards enforced by the certification.
The Company's successful completion of this audit, along with its continued commitment to protecting sensitive data and information, reinforces its position as a trusted partner in the industry and in patient care. Continued conformity with this standard means that Verici Dx's system meets world-wide best practice with regards to managing risks related to the security of data owned or handled by the Company.
Dave Schultenover, VP Quality and Regulatory Affairs at Verici Dx, said: "We take our commitment to compliance at Verici Dx very seriously and pride ourselves on performing with integrity that meets or exceeds industry regulations and standards. We are pleased maintain this strong track record to remain a trusted partner with our stakeholders and within the industry."
| Verici Dx plc
|
||
| Sara Barrington, CEO |
Via Walbrook PR |
|
|
|
|
|
| Singer Capital Markets (Nominated adviser, Joint Broker) |
Tel: +44 (0)20 7496 3000 |
|
| Phil Davies / Sam Butcher |
|
|
|
|
|
|
| Oberon Capital (Joint Broker) |
Tel: +44 (0)20 3179 0500 |
|
| Mike Seabrook / Adam Pollock |
|
|
|
|
|
|
| Walbrook PR (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
| Alice Woodings / Paul McManus |
Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893 |
|
|
|
|
|
|
|
||
